RxDoctor Payments Data

Farid Eghbali, OD

Optometrist · Burbank, CANPI 1386614386

Payments from drug & device makers

$4,505in general payments, 2019–2025

Across 76 payments — averaging $59.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumenis BE Inc$2K
  • Alcon$616
  • Sun Pharmaceutical Industries Inc.$297
  • Johnson & Johnson Vision Care, Inc.$275
  • Tarsus Pharmaceuticals, Inc.$216
  • Novartis$131
  • plus $519 from 12 others

What the payments were for

  • Food & beverage$4,48199%
  • Education$60%
  • Other$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,505 in reported general payments places this provider in the 90th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$138,710
Medicare patients
452
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine144$126,788
LumiganBimatoprost190$71,854
Cyclosporine121$47,053
XiidraLifitegrast23$18,350
Restasis MultidoseCyclosporine22$17,207
CequaCyclosporine26$15,910
SimbrinzaBrinzolamide/Brimonidine Tart35$12,508
Alphagan PBrimonidine Tartrate37$8,853
Latanoprost1,242$8,675
Travoprost39$8,032
CombiganBrimonidine Tartrate/Timolol27$7,661
VyzultaLatanoprostene Bunod20$7,371
Brimonidine Tartrate148$6,852
Brinzolamide43$6,486
Timolol Maleate315$2,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Alphagan P, Combigan$123$232,363420 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$48$25,72143 claims
Sun Pharmaceutical Industries Inc.Cequa$297$15,91026 claims
AlconSimbrinza$616$12,50835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,778 optometrist providers in California.

Other optometrist in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →